comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 12:35:08 - browse：9863

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Would Medicare drug price negotiations stall in a shutdown?

WSS

Intercept Pharmaceuticals sells itself for less than $1 billion

How one patient went off dialysis — and others can too

Medicare Advantage enrollment hits roughly 33.4 million

Hospitals are piloting generative AI tools as regulators play catch

Mindstrong's demise and the future of mental health care

FDA seeks to regulate lab

focus

comprehensive

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

23andMe had bad news about my health. I wish a person had delivered it

Kaiser Permanente unions announce official strike date

What does generative AI mean for health care? We asked experts

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Medical leaders decry Supreme Court decision on affirmative action

Elevance, SCAN deals highlight health insurer acquisition scrutiny

State Dept. review finds Biden bears some blame for Afghanistan failures

WATCH: Why do our ears pop?

hotspot

Medicare Advantage enrollment hits roughly 33.4 million

Surprise medical billing ban raises prices elsewhere

New study raises questions about niacin and heart health

Inequities make cancer less preventable for women: report

A new drug could help frostbite victims avoid its ravages

Hospitals are piloting generative AI tools as regulators play catch

Wikipedia

hotspot

explore

entertainment